BPC
MDGL icon

Bryce Point Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bryce Point Capital’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$536K Buy
+1,169
New +$436K 0.65% 76
2025
Q1 		– Sell
-1,903
Closed -$587K – 344
2024
Q4 		$587K Buy
+1,903
New +$535K 0.17% 167

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Bryce Point Capital's MDGL Position: Q3 2025 in Review

Bryce Point Capital opened a new position in Madrigal Pharmaceuticals (MDGL) in Q3 2025: 1,169 shares worth $536K. The stake represents 0.65% of the portfolio and ranks #76 among its holdings. This is a return to the name: Bryce Point Capital previously reported a position in MDGL as recently as Q4 2024.

Bryce Point Capital first reported a position in MDGL in Q4 2024 and has held it in 2 quarters since. The position peaked at $587K in Q4 2024. 352 funds tracked by Wall St. Rank hold MDGL as of Q3 2025.

  • Bryce Point Capital held 1,169 shares of Madrigal Pharmaceuticals worth $536K as of Q3 2025.
  • Madrigal Pharmaceuticals was a new Bryce Point Capital position in Q3 2025.
  • Madrigal Pharmaceuticals made up 0.65% of Bryce Point Capital's portfolio in Q3 2025, its #76 holding.
  • Bryce Point Capital first reported a position in Madrigal Pharmaceuticals in Q4 2024 and has held it in 2 quarters since.
  • Bryce Point Capital's Madrigal Pharmaceuticals position peaked at $587K in Q4 2024.
  • 352 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2025.

Based on Bryce Point Capital's 13F filing for Q3 2025, filed 6 Nov 2025.